Combination therapy after prostate removal for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether taking a drug called apalutamide (combined with hormone therapy) after prostate removal helps prevent the cancer from returning. It is for men whose prostate cancer has a high risk of coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 to 75.
- Your prostate was removed because of cancer, and this was within the last 12 weeks.
- Your PSA (prostate-specific antigen) level was below 0.1 ng/mL within 8 weeks after surgery.
- Your doctor calculates your risk of the cancer coming back as high (a CAPRA-S score of 6 or more).
- You are generally in good health, with adequate liver, kidney, and blood cell function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
This trial compares two ways of giving hormone therapy (apalutamide) along with radiation after prostate removal surgery. It aims to see which approach helps maintain quality of life while controlling cancer.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.